IP Verse

Teva competitive analysis

Latest oppositions filed by Teva

Explore patent oppositions filed by Teva against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026

Patent Number	Title	Applicant	Opposition Date
EP3694522	Bi-Layer Pharmaceutical Tablet Formulation	VIIV HEALTHCARE	Aug 26, 2026
EP2396005	Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or Hyperglycemia	BOEHRINGER INGELHEIM	Aug 13, 2026
EP3856182	Compositions And Methods For Treating Disorders Ameliorated By Muscarnic Receptor Activation	KARUNA THERAPEUTICS	Jul 30, 2026
EP3834824	Method Of Treating Cancer Using Selective Estrogen Receptor Modulators	DUKE UNIVERSITY	Jul 20, 2026
EP3984538	Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene	AMICUS THERAPEUTICS	Jul 20, 2026
EP3823631	Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same	ASTRAZENECA	Jul 15, 2026
EP3860594	Biphenyl Sulfonamide Compounds For The Treatment Of Type Iv Collagen Diseases	TRAVERE THERAPEUTICS	Jun 30, 2026
EP3836920	Formulations Of Ag10	EIDOS THERAPEUTICS	Jun 23, 2026
EP4188389	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	ASTRAZENECA	Jun 9, 2026
EP3676404	Methods Of Selecting A Treatment For Cancer Patients	NOVARTIS	Jun 2, 2026

Latest patents of Teva opposed by its competitors

Explore Teva's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026

Patent Number	Publication Date	Title	Total Oppositions
EP3798224	Mar 19, 2025	Solid State Forms Of Ixazomib Citrate	1
EP4097091	Sep 18, 2024	Solid State Forms Of Mavacamten And Process For Preparation Thereof	3
EP3554581	Mar 13, 2024	Medical Injection Device Packaging	2
EP3497104	Oct 6, 2021	Solid State Forms Of Lumateperone Ditosylate Salt	1
EP3344607	Nov 6, 2019	Solid State Forms Of Selexipag	2
EP2897588	Jul 17, 2019	An Inhalable Medicament	1
EP3143998	May 22, 2019	An Inhalable Medicament Comprising Tiotropium	1
EP2508523	Apr 17, 2019	Polymorphs Of Dasatinib And Process For Preparation Thereof	1
EP1848402	Feb 20, 2019	Rasagiline Formulations Of Improved Content Uniformity	1
EP3045182	Mar 7, 2018	Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using Same	2

Latest PTAB cases involving Teva

Discover the latest PTAB cases involving Teva, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 5, 2026

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Teva
IPR2022-01513	Sep 9, 2022	TEVA PHARMACEUTICALS	BAYER PHARMA	Terminated-Adverse Judgment
IPR2022-00796	Apr 11, 2022	ELI LILLY	TEVA	Final Written Decision
IPR2022-00796	Apr 11, 2022	ELI LILLY	TEVA PHARMACEUTICALS	Final Written Decision
IPR2022-00738	Mar 23, 2022	ELI LILLY	TEVA	Final Written Decision
IPR2022-00738	Mar 23, 2022	ELI LILLY	TEVA PHARMACEUTICALS	Final Written Decision
IPR2022-00739	Mar 23, 2022	ELI LILLY	TEVA	Final Written Decision
IPR2022-00739	Mar 23, 2022	ELI LILLY	TEVA PHARMACEUTICALS	Final Written Decision
IPR2020-01045	Jun 10, 2020	TEVA PHARMACEUTICALS	CYPES	Terminated-Settled
IPR2020-01045	Jun 10, 2020	TEVA PHARMACEUTICALS	MERCK SHARP & DOHME	Terminated-Settled
PGR2019-00048	May 7, 2019	TEVA PHARMACEUTICALS	CORCEPT THERAPEUTICS	Final Written Decision

Peer Comparison New

IP litigation analysis comparing Teva with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
TEVA	3	-	-	12
ELI LILLY	18	33	17	15
MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT	3	9	-	-
NEURODERM	-	1	1	-